Lead Sponsor

Radboud University Medical Center

Collaborators

Age

18 - 65 years

Sex

ALL

Healthy Volunteers

Yes

•at least 18 and no older than 65 on the day of first dosing
•healthy
•Quetelet Index (Body Mass Index) of 18 to 30 kg/m2
•In general, results of haematology and chemistry should be within the laboratory's reference ranges. Determinants of renal and hepatic function should be within twice the upper limit of normal range.

•Documented history of sensitivity / idiosyncrasy to medicinal products or excipients
•history of smoking within the past year
•history of or current abuse of drugs, alcohol and/or solvents
•Current use of any (over the counter) medication potentially influencing heme oxygenase or the cardiovascular system
•Inability to understand the nature and extent of the trial and the procedures required
•Participation to a drug trial within 60 days prior to the first dose
•Febrile illness within 3 days before the first dose
•Heterozygosity (LS) or homozygosity (LL) with regard to the number of GT repeats in the HO-1 promoter region

Related studies

NCT05485961 · Atherosclerotic Cardiovascular Disease in Patients With ESKD

NCT07487363 · Atherosclerotic Cardiovascular Diseases, Endothelial Dysfunction

NCT06813911 · Atherosclerotic Cardiovascular Disease (ASCVD)

NCT06295679 · Major Cardiovascular Event, Established Atherosclerotic Cardiovascular Disease

NCT06930885 · Atherothrombotic Diseases, Atherosclerotic Cardiovascular Disease (ASCVD)

Heme Oxygenase (HO) Activity and Adenosine Induced Vasodilation